Medifast (MED) Stock Price, News & Analysis

Company Overview

Medifast, Inc. (NYSE: MED) is a health and wellness company that provides weight-management and healthy-lifestyle products and programs. Its principal brand is OPTAVIA, which offers structured plans designed to support weight loss, nutrition, and long-term habit development.

The company’s product portfolio includes meal-replacement shakes, bars, snacks, entrees, beverages, supplements, and other packaged “Fuelings.” Medifast also supports customers through independent OPTAVIA Coaches, who provide guidance, accountability, and lifestyle support through the company’s direct-selling model.

Founded in 1980, Medifast serves customers primarily in the United States through its e-commerce and direct-to-consumer channels. The company has evolved from offering physician-directed weight-loss products into a broader wellness business centered on OPTAVIA’s integrated products, programs, and coaching services.

Key Stats

• Today's Range: $12.08 to $12.48
• 50-Day Range: $9.44 to $13.12
• 52-Week Range: $9.22 to $14.65
• Volume: 72,553 shs
• Average Volume: 112,643 shs
• Market Capitalization: $135.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Reduce

Medifast Stock Analysis - MarketRank™

Medifast scored higher than 23% of companies evaluated by MarketBeat, and ranked 144th out of 171 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Reduce

Consensus Rating

Medifast has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Medifast is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Medifast has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Medifast are expected to grow in the coming year, from ($1.04) to ($0.47) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Medifast is -5.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Medifast is -5.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Medifast has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.49% of the float of Medifast has been sold short.

Short Interest Ratio / Days to Cover

Medifast has a short interest ratio ("days to cover") of 15.11, which indicates bearish sentiment.

Change versus previous month

Short interest in Medifast has recently increased by 3.22%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Medifast does not currently pay a dividend.

Dividend Growth

Medifast does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: N/A

News Sentiment

Medifast has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Consumer Staples companies.

Search Interest

Only 2 people have searched for MED on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

1 people have added Medifast to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.7 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $1,423,576.00 in company stock, which represents 1.0480% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Medifast insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,423,576.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

3.70% of the stock of Medifast is held by insiders.

Percentage Held by Institutions

95.51% of the stock of Medifast is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/03/2026
• Today: 9/23/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Consumer Staples
• Industry: Personal Care Products
• Sub-Industry: Personal Care Products
• Current Symbol: NYSE:MED
• CIK: 910329
• Web: www.medifastinc.com
• Phone: (410) 581-8042
• Fax: 410-581-8070
• Employees: 380
• Year Founded: 1981

Price Target and Rating

• Average Price Target for Medifast: $12.00
• High Price Target: $12.00
• Low Price Target: $12.00
• Potential Upside/Downside: -1.2%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.33)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.67 million
• Net Margins: -8.08%
• Pretax Margin: -4.41%
• Return on Equity: -6.69%
• Return on Assets: -5.25%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.86
• Quick Ratio: 4.35

Sales & Book Value

• Annual Sales: $385.79 million
• Price / Sales: 0.35
• Cash Flow: $0.41 per share
• Price / Cash Flow: 29.54
• Book Value: $18.10 per share
• Price / Book: 0.67

Miscellaneous

• Outstanding Shares: 11,180,000
• Free Float: 10,767,000
• Market Cap: $135.84 million
• Optionable: Optionable
• Beta: 0.71